Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Would love to know more about the UK NHS as we are also researching potential....
Remember this PCTL announcement April 2020
PCT EUROPE LTD SIGNS DISTRIBUTION AGREEMENT WITH UK NHS COMPANY, RECEIVES ADDITIONAL NYC HOSPITAL ORDER
Little River, South Carolina — (April 16, 2020) – PCT LTD (OTC Pink: PCTL) is pleased to announce new growth and expansion activities in the UK and NYC. PCT Europe Ltd, the UK-based partner of PCTL is pleased to announce they have signed an exclusive trading partnership/distributor agreement with an NHS (U.K. National Health Service) company.
In tandem with PCT Europe Ltd, the UK NHS company will introduce PCT technology to each NHS Hospital Trust with the intention of them rolling out PCT’s unique technology and system throughout the health services 233 Trusts comprising over 600 hospitals. In addition, approximately 14,000 Care Homes in the U.K. will also be introduced to PCT’s technology. A steady flow of orders is expected to commence throughout the remainder of 2020 and into 2021. The first PCT system has now been installed in a large NHS hospital in the north of England. This system is expected to enter clinical service early in May once the final series of biological tests of the PCT hospital disinfectant solution have been completed. Results of these tests have so far demonstrated that the PCT disinfectant has met or exceeded its ability to kill the range of pathogens previously achieved during EPA tests in the United States.
“We couldn’t be happier with the results thus far in our UK trials and are delighted with the progress our UK partner is making. This arrangement will introduce our system to thousands of hospitals and healthcare facilities,” says PCTL CEO Gary Grieco. “At the same time, the reality of the current healthcare crisis both domestically and abroad is sobering. We’re thrilled to be able to grow our business but nevertheless remain focused on our core mission which from day one has always been helping people.”
The company continues to expand domestically as well. Following an earlier release dated April 14th, the company is also announcing an additional purchase order for PCT Corp.’s Annihilyzer® Infection Control Systems in New York City.
The order comes from a large NYC hospital with a current bed count in excess of 1000. Installation will be made in coordination with PCT Corp’s primary healthcare distributor, ACE Janitorial Services.
“With three PO’s for our infection control system this week and more on the way, we continue to make strides both in growing our business as well as our goal of helping our clients fight the spread of infectious diseases,” says Grieco. “We are on pace for unprecedented and record growth in all areas of our business"
PCT Europe Ltd is a dormant company today having never traded - see UK Company records - https://find-and-update.company-information.service.gov.uk/company/10240228/filing-history
TUTUM Health Ltd dead company with £ 300,000 debt - https://find-and-update.company-information.service.gov.uk/company/12822771/filing-history
News from UK is that Pathisol PCTL generator has been removed from NTH Solutions site in North Tees and no longer part of any UK NHS trials. TUTUM Health moved the NHS PCTL HOCL generator to a small company in Scotland called Environmental Business Solutions new selling their own brands of HOCL for pets and horses. Looks like any PCTL UK NHS is dead. See - https://eb-s.co.uk/ and their Facebook pages at - https://www.facebook.com/EnvironmentalBusinessSolutions01/ where you will now see Pathisol rebranded as Chlorisal and Chloripet....
Thanks Dade - What is sad is the amount of hard work and investment Tutum Health and the guys at NTH Solutions made, trying their very best to promote Pathisol (PCTL's HOCL UK brand name) in the UK and then find their source of supply change.
Does anyone know who has taken over supplying PCTL's healthcare client base..?
UK's PCTL HOCL competitors - There are numerous UK and European companies actively marketing and selling, the leading NHS provider being Aqualution - https://www.aqualution.co.uk/ who not only supply NHS direct but white-label for many other companies.
NTH Solutions are very professional at cleaning and disinfection procedures and staff training, and is why they adopted and support Pathisol.
How PCTL has treated its loyal healthcare clients is disgusting.
May I ask a very basic question - if healthcare has been sold off what happened to the United Kingdom agency...? Where do they get their HOCL equipment from now...as they are trying hard to promote PCTL's HOCL with UK healthcare ..... ?
Today NTH Solutions present the Pathisol University reports to a NHS Knowledge Exchange near Birmingham UK where @ 200-plus select and key NHS personnel attend, with a number of leading disinfectant and other trade exhibitions. NTH have a afternoon workshop on Pathisol which is not a mainstream discussion therefore not all at the event will attend their presentation, which reveals the in-hospital trials results. One of our key staff will be there. That report may support Pathisol but is also generically supports any other Hypochlorous Acid from their many competitors, just reinforcing the overall advantages of any HOCL. Methis Health delivered a similar report over a year ago and still got nowhere within the NHS nationally and are exhibiting. The really BIG issue with Pathisol is the 30 day lifespan which no other HOCL suffers from due to the poor electrolysis chemistry created by PCTL. All others last months. The logistics recovering 30 day old Pathisol in a huge hospital is a nightmare scenario. To date no major NHS Trust has fully adopted HOCL, even NTH's own Trust, as from recent reporting NTH now has to deliver their Business Plan to their own NHS Board. There is a long way to go yet with any HOCL never mind Pathisol. Realistically, even if Pathisol was a major success at today's NHS meeting it is likely the first real orders would be due in sometime early 2023 around March, and that's only their own NHS Trust in North Tees, if their Board agrees adoption. Maybe worth @ $ 80,000 of self generated HOCL, therefore no real UK income stream for PCTL except 'good' news to try to pump up share value. If you want solid DueDil this is where the UK now stands regarding PCTL & NTH Solutions/Tutum.
As stated before - this is history - way back earlier this year.....
To date we do not know that PCTL's HOCL was finally tested
On pages 46 to 47 of that meeting NHS Trust report it is clear the managing Board needs a lot more data and proof before adoption - quoting this paragraph ..... "The Chair confirmed a full business case would be presented to the Board based on ICP evidence, cost improvement, performance of solution and sustainability benefits considered with the governors kept in touch on progress" .....which means the North Tees NHS Trust will continue to use its present disinfection products until it is proven that HOCL is sustainable, performs and is cost-effective and as we all know, PCTL's HOCL is very short longevity therefore it is highly probable NTH Solutions have changed to a more effective longer-term HOCL for this critical trial, then add the fact that this meeting report confirms that HOCL is not generally used by UK NHS which means even if NTH Solutions deliver a rock solid report and Business Case to their NHS Trust Board, it will take months to see general adoption by that single NHS Board and Trust, and even longer to convince any other UK NHS Trust to drop present products and move to NTH's HOCL, or another competitors.
At that same 20th September NCC Conference competitors like Methis Health and Hibrisan are Sponsors and will have booths selling their products, Methis having a far better quality HOCL than PCTL's.
Trying to sell to the wider UK NHS is going to be very hard and will take well into 2023, 2024 onwards. No quick gains.
Then add the fact that once that University HOCL effectiveness report arrives it also confirms the generic attributes of any other HOCL around 500ppm which opens the door to numerous HOCL competitors like Methis Health and others using that same generic HOCL @ 500ppm efficacy data.
There is nothing special about HOCL as others make as-good-as or even better.
Ultimately that North Tees Board statement above (Pages 46-47) is what governs adoption policy everywhere in the UK NHS system.of 219 Trusts.
Not all will move to HOCL.
Take-up maybe as low as 10% over five years marketing.
Even if 10% adopted that is 21 UK NHS trusts that may or may not buy a PCTL's machine therefore gross revenues are poor over time, plus other make far better machines.
It is no big-deal to secure UK NHS adoption in fiscal terms as this is a highly competitive market in both EU and UK.
That is all history......
No doubt that was the situation some months ago.
What is today's position...?
About time this is verified - as should NTH Solutions and NHS tested another sourced HOCL under the Pathisol brand, then the PCTL UK NHS linkup is dead.
A bit of sensible investor or PCTL's DueDil is required to ascertain facts from fiction seeking a legally binding declaration from TUTUM or NTH Solutions that PCTL's in-hospital generated HOCL was the liquid used in the recent University testing.
Who knows if this is the PCTL's HOCL or as many believe, and entirely new source non-PCTL under the Pathisol brand.... It is about time it was confirmed who's HOCL now fills a UK NHS tested Pathisol bottle....?
Dear Godogh
We are EU based and not UK, and as we are not PCTL investors, it is very-much up to you and your colleagues to verify information. We keep monitoring disinfectant products, manufacturers EU & UK-wide and especially claims made. We manufacture a range of non-HOCL products and like many in this trade, we are concerned that low quality product is entering the market under the name of UK NHS. Fair competition is OK. Abuse of a key marketing advantage is not. It's your money folks so do your own investigations. We have, and like others here, have serious concerns.
Namtae - It really does matter which HOCL. PCTL is at the lowest end of the market for poor quality HOCL with a inferior machine compared to top class competitors with far better quality HOCL lasting far longer in containers and better machinery capable of 1000ppm up to 4000ppm, many with internet connectivity to the manufacturer to monitor, service and adjustments. PCTL is up against some highly capable competitors and is the sole reason PCTL's sales are so poor. Then consider that 90% potential customers do not use HOCL, having adopted other chemicals that they consider adequate. To change those to HOCL is a massive task.
Simple answer is to seek a signed written response from TUTUM confirming that PCTL's HOCL is being used by NTH Solutions on the NHS trials...?
The Annihilizer may still be on NHS premises, but exactly what/whos HOCL is being tested...?
If everyone is so clever referring to SDS's etc.... why is it that TUTUM & NTH have to date only quoted 500ppm and now shifted a few weeks ago to quoting 600ppm....?
Has anyone recently checked Pathisol advertizing on UK website NTH Solutions.
The latest Pathisol being sold is now quoted at 600ppm not 500ppm which indicates PCTL's HOCL is no longer the selected product.
If so PCTL's HOCL generator within the UK NHS is also dead.....
It's obvious NHS & NTH Solutions have dropped PCTL and moved elsewhere, unless PCTL has created a 'new' HOCL at 600ppm...?
This means the ongoing NHS hospital testing with Tyneside University is with another product (still called Pathisol by NTH Solutions) and not PCTL's.
We all wonder if Tutum Health have informed PCTL they are out the UK NHS game...?
Dear TCaine
We are scientists and analysts commissioned to do a Due Diligence on this TUTUM North Tees HOCL program. We deal in facts and figures. It appears a lot of 'creative' material has been circulated that needs reviewing and assessing. Procurement by a Public Entity such as the UK NHS follows strict protocols. It would be very unwise to attempt to deviate from mandated procedures. Open competition follows proven EU & UK Tendering stages called PreQualification Questionnaires (PQQ's) and then Invitation To Tender (ITT's) therefore competitors equally have the opportunity to make detailed counter-offers. There are no Monopolies as a result. No-one can predict or make promises about possible UK & EU end-results until that individual tendering process is completed and a final decision is made by that buying agency. Even then there is a 2 week stand-off period allowing counter-challenge to the chosen winner. There are 219 UK NHS Trusts and 10 UK Ambulance Trusts which makes cross-marketing a seriously challenging process. Success in one doesn't result in any others buying anything.
Dear snow
Let's look at the processes behind new concept adoption. Well before COVID every nation has some form of hygiene and disinfection program in-place with authorized products. The UK NHS has over 200 authorized disinfectants on their Procurement lists, five being HOCL from various sources both UK and EU. One prime UK supplier is Aqualution. Once listed each of the numerous UKI NHS Trusts can make their own individual purchase decisions, and have done during the pandemic, purchasing $millions worth of diverse hygiene related products. TUTUM is a late starter and is viewed just another HOCL bit very cleverly they tied up with one single NHS Trust in North Tees. That trust as a commercial division that is allied to TUTUM to market Pathisol and if possible, the PCT HOCL machinery. In the past two years very little progress has been made apart from an impressive website and the slowly developing relationship with that single NHS Trust commercial arm. Preliminary HOCL trials took place over a few weeks giving encouraging results however any generic HOCL @ 500ppm would have give identical results. Now, with those initial statistics the NHS Trust allowed a multi-week live trial in one North Tees hospital, the results to be recorded, analyzed and then published. Pathisol is the product being tested however, please remember that this is a generic HOCL therefore once that individual Trust approves use of 500ppm HOCL then the opportunity opens for all other HOCL providers, including those that supply HOCL generation machines, to offer counter-bids, some being lease and some outright purchase. There are some very competitive prices for HOCL generators far better that the aged technologies PCT use, plus other HOCL's are more long-term stable. It is mandated that any NHS Trust that decides to commit to over £ 20k purchases must open a Tender process and assess all viable options. Even if TUTUM/Pathisol passed a in-use test process that is not a guarantee they would win business, as that NHS Trust and all others must seek best Value For Money any any attempt to evade that process would see HOCL competitors open legal challenges seeking fair play. Even if North Tees adopted Pathisol and the PCT machine, then TUTUM's really hard work begins to sell to all the other UK NHS Trusts, which would take TUTUM well into 2023 & 2024 as UK Fiscal Year budgets run end-March therefore votes for spend would fall in FY 2023-24 and not this FY 2022-23. Parallel to any TUTUM endeavours every single Trust would be bombarded by powerful HOCL competitors waging price wars and technology advantages, with solid supply chain promises and backup, and this is where the debt PCT carries would be used as a weapon against them, as underfunded, the risk of PCTL future collapse is very real. Other HOCL suppliers are well funded and technologically ahead. The only way TUTUM could resolve this real risk to their profile and credibility is to drop working with PCT and find another more advanced HOCL machine supplier. TUTUM could still call the product Pathisol, but unconnected with PCTL. The White Paper would signal the start of commercial warfare that will then persist for years to come, plus many NHS Trusts will just ignore North Tees and Pathisol and carry on buying their current products. There are absolutely NO guarantees any SIGNIFICANT sales will occur.
The same rules apply to all EU states. To successfully compete in this Game of Thrones TUTUM needs serious funding to extensively market both Pathisol and a HOCL generating device in both UK and EU. After COVID struck virtually every US cruise ship and many other 'flags' adopted on-board HOCL generation,as sea water being salt rich is the ideal source medium, and that is why so many top class competitive HOCL generators exist today. There are very markets where anyone has any monopoly, unless they have a unique process or technology backed by Patents and solid IPR.
Dear Mugwumps88
My team and I were there, talking with Infection Control delegates and other exhibitors. Having worked these last 35 years in this subject at UK National Government level, we do not need to resort to BS. It seems the whole PCT/TUTUM and UK NHS story is very well scripted to appear to be much better than it actually is. Pathisol is just another HOCL of many, and will face serious challenges once NHS and other tenders are published. Due to post-COVID semi-Recession any NHS contract/s to buy HOCL machines and liquids will be fiercely contested as suppliers will resort to every dirty trick in the book. PCL's weak finances and fierce competition from far more powerful and competent suppliers will be a real challenge. If TUTUM try to bluff their NHS inside-track position and then are exposed, proven to be false, they and Pathisol are game over. Here in the UK open-tendering is mandatory with ITT & PQQ's eliminating lesser suppliers. The same applies to all EU tenders. It will be very interesting to see how this story unfolds. Any 'white-paper' will be closely scrutinized. If there in any attempt to bluff will have commercially fatal consequences to them and those partnering them. Too many people are now watching.....
Where is the long promised UK White Paper...?
At a recent UK NHS Conference & Exhibition TUTUM Pathisol was heavily promoted with grand claims about direct NHS connections leading to more detailed investigations into who exactly are TUTUM and their NHS status which seems soley tied to two guys Tony Sullivan & Graeme Kelly employed by NHS North Tees Trust as Infection Control trainers making this promised White Paper not an truly independent official test but a TUTUM generated localized use of Pathisol using their own people. Whatever the White Paper will reveal is therefore suspect as not truly an independent Third Party assessment. At a Scottish NHS Infection Control Conference a few weeks ago a number of delegates discussed TUTUM and Pathisol with obvious TUTUM misinformation about true Pathisol ppm's and longevity once generated. Dwell times were not revealed. As a real HOCL expert was present, certain pro-Pathisol delegates were told about true HOCL performance, negatives as well as positives. TUTUM really needs to be very careful about misusing their claimed NHS affiliations as some people are now looking very closely into TUTUM's advertising, unsubstantiated claims made and potential misuse of their true NHS status. NTH Solutions is the NHS link, not TUTUM. TUTUM is a UK registered private company facing really strong UK competitors such as Aqualution who offer far better and lower cost stable HOCL than Pathisol. If TUTUM did create any real NHS interest in both Pathisol and especially the US PCT Ltd Pathisol Annihilyzer machine there are numerous UK and EU direct competitors who will offer viable alternative HOCL options, as all UK NHS Trusts have to publish tenders before selecting a supplier which means TUTUM and PCT USA are not guaranteed any UK NHS exclusivity should generic HOCL be specified. The results of the long promised White Paper once published will alert every HOCL competitor to offer their far better products and machinery, all from 100% fully funded and financially solvent sources. NHS Trusts will no-doubt be told that PCT USA is insolvent and could collapse making purchasing an Annihilyzer an unwise decision, as should PCT cease trading means no spares and backup. It is therefore highly likely competitors will use open-source US stock market information to their advantage and commercially savage Pathisol, PCT Ltd and their Annihilyzer.